Kymera Therapeutics, Inc. (KYMR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kymera Therapeutics, Inc. (KYMR) Healthcare & Pipeline Overview

Kymera Therapeutics, Inc. pioneers targeted protein degradation therapeutics, developing small molecule drugs for immunology-inflammation, oncology, and other diseases. With a focus on novel mechanisms, Kymera aims to address previously undruggable targets, positioning itself in the competitive biotechnology landscape alongside companies like Praxis Precision Medicines, Inc. and Arcellx, Inc.

What Is the Investment Thesis for KYMR?

Kymera Therapeutics presents a compelling, albeit high-risk, investment thesis centered on its innovative targeted protein degradation platform. The company's approach to drug discovery offers the potential to address previously undruggable targets, creating significant value if clinical trials are successful. Key value drivers include the advancement of its IRAK4 program through clinical trials and the progress of its other pipeline programs. The company's $9.62B market cap reflects investor optimism, but also highlights the execution risk associated with early-stage biotechnology companies. Upcoming clinical trial results will serve as major catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies, including Praxis Precision Medicines, Inc. and Arcellx, Inc.

Based on FMP financials and quantitative analysis

KYMR Key Highlights

Market capitalization of $9.62B, reflecting strong investor confidence in the company's technology and pipeline.

• Gross margin of 100.0%, indicating efficient management of research and development costs.
• Profit margin of -612.2%, typical for a pre-revenue biotechnology company heavily investing in research and development.
• IRAK4 program in Phase I clinical trial, targeting a range of immunology-inflammation diseases.
• Beta of 2.29, indicating higher volatility compared to the overall market.

Who Are KYMR's Competitors?

KYMR is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KYMR's Key Strengths?

Innovative targeted protein degradation platform.

• Strong intellectual property portfolio.
• Experienced management team.
• Promising early-stage clinical data.

What Are KYMR's Weaknesses?

Early-stage company with limited revenue.

• High research and development costs.
• Reliance on clinical trial success.
• Competition from larger pharmaceutical companies.

What Could Drive KYMR Stock Higher?

Clinical trial results for the IRAK4 program in immunology-inflammation diseases.

• Advancement of the IRAKIMiD program into later-stage clinical trials for MYD88-mutated diffuse large B cell lymphoma.
• Initiation of clinical trials for the STAT3 program in hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis.
• Expansion of the targeted protein degradation platform to new disease targets.
• Strategic partnerships and collaborations with larger pharmaceutical companies.

What Are the Key Risks for KYMR?

Negative return on equity (-25.0%) — the business is not currently generating profit on shareholder capital.

• Clinical trial failures for any of its pipeline programs.
• Regulatory hurdles and delays in obtaining marketing approvals.
• Competition from other biotechnology companies developing similar therapies.
• High research and development costs.
• Dependence on key personnel and scientific expertise.

What Are the Growth Opportunities for KYMR?

• Expansion of IRAK4 program: Kymera has the opportunity to expand the IRAK4 program beyond its current indications to address other immunology-inflammation diseases. The market for immunology-inflammation therapies is substantial, with a global market size estimated at billions of dollars. Successful clinical trials and regulatory approvals could drive significant revenue growth for Kymera. The timeline for expansion depends on clinical trial results, but potential new indications could be pursued within the next 3-5 years.
• Advancement of IRAKIMiD program: The IRAKIMiD program targets MYD88-mutated diffuse large B cell lymphoma, a hematologic malignancy with limited treatment options. Positive clinical data and regulatory approval could position Kymera as a leader in this niche market. The market for lymphoma therapies is growing, driven by an aging population and increasing incidence rates. Clinical trials are ongoing, with potential for regulatory submission within the next 3-4 years.
• Development of STAT3 program: The STAT3 program targets hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis. This broad applicability offers significant growth potential for Kymera. The market for STAT3-targeted therapies is estimated at billions of dollars, with potential for further expansion as new indications are explored. Preclinical and early clinical development are underway, with potential for later-stage clinical trials in the next 2-3 years.
• Strategic partnerships and collaborations: Kymera can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline programs. These partnerships can provide access to funding, expertise, and global distribution networks. The biotechnology industry is characterized by frequent collaborations, with many companies seeking to leverage external innovation. Potential partnerships could be pursued in the near term, with the goal of accelerating clinical development and commercialization.
• Expansion of targeted protein degradation platform: Kymera can expand its targeted protein degradation platform to address new disease targets and therapeutic areas. This platform offers the potential to develop therapies for a wide range of diseases, including those that have been historically difficult to treat. The market for targeted protein degradation therapies is emerging, with significant growth potential as the technology matures. Kymera's expertise in this area could provide a competitive advantage, with new targets being explored on an ongoing basis.

What Are KYMR's Competitive Advantages?

• Proprietary targeted protein degradation platform.
• Strong intellectual property portfolio protecting its therapies and technologies.
• Expertise in protein degradation biology and drug discovery.
• First-mover advantage in the emerging targeted protein degradation market.

What Does KYMR Do?

Kymera Therapeutics, Inc., founded in 2015 and headquartered in Watertown, Massachusetts, is a biopharmaceutical company dedicated to discovering and developing breakthrough protein degradation therapies. The company's core technology harnesses the body's natural protein degradation system to selectively eliminate disease-causing proteins. This approach offers the potential to address a wide range of diseases, including those that have been historically difficult to treat with conventional therapies. Kymera's pipeline includes programs targeting immunology-inflammation diseases, hematologic malignancies, solid tumors, and autoimmune diseases. Their lead program, IRAK4, is currently in Phase I clinical trials for the treatment of immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis. Other key programs include IRAKIMiD for MYD88-mutated diffuse large B cell lymphoma, STAT3 for hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis, and MDM2 for hematological malignancies and solid tumors. Kymera's innovative approach and promising early-stage clinical data have attracted significant investor interest, as reflected in its substantial market capitalization.

What Products and Services Does KYMR Offer?

• Develops small molecule therapeutics for targeted protein degradation.
• Focuses on degrading disease-causing proteins using the body's natural protein degradation system.
• Targets immunology-inflammation diseases, hematologic malignancies, and solid tumors.
• Conducts preclinical and clinical research to evaluate the safety and efficacy of its therapies.
• Seeks regulatory approval for its therapies from agencies like the FDA.
• Aims to commercialize its therapies and make them available to patients.

How Does KYMR Make Money?

• Develops and patents novel small molecule therapeutics.
• Out-licenses or co-develops its therapies with larger pharmaceutical companies.
• Generates revenue through milestone payments, royalties, and product sales.
• Focuses on research and development, with a significant portion of its expenses allocated to these activities.

What Industry Does KYMR Operate In?

Kymera Therapeutics operates within the competitive and rapidly evolving biotechnology industry. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The targeted protein degradation market is an emerging field with the potential to disrupt traditional drug discovery approaches. Kymera competes with other biotechnology companies, including Praxis Precision Medicines, Inc. and Arcellx, Inc., that are developing novel therapies for similar disease areas.

Who Are KYMR's Key Customers?

• Patients suffering from immunology-inflammation diseases, hematologic malignancies, and solid tumors.
• Healthcare providers who prescribe and administer Kymera's therapies.
• Pharmaceutical companies that partner with Kymera to develop and commercialize its therapies.
• Payers, including insurance companies and government healthcare programs, that reimburse for Kymera's therapies.

Return on equity for Kymera Therapeutics, Inc. stands at -25.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.8%, the inverse of the P/E and a quick read on earnings relative to price.

Quarterly Financial Performance: Kymera Therapeutics, Inc.

Revenue for Kymera Therapeutics, Inc. came in at $65.0M during Q2 FY2026, a 89.1% improvement versus the preceding quarter. The company recorded a net loss of $61.2M, with diluted EPS of $-0.62. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, KYMR averaged $-0.81 in diluted EPS.

KYMR Valuation & Market Position

With a $9.62B market cap, Kymera Therapeutics, Inc. sits in the mid-cap segment of the market.

Company Profile

Kymera Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Nello Mainolfi. KYMR has traded publicly since 2020.

KYMR Financials

KYMR Latest News

No recent news available for KYMR.

KYMR Analyst Consensus

KYMR MoonshotScore

What Investors Ask About Kymera Therapeutics, Inc. (KYMR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources